Image Credit: © ipopba – stock.adobe.com
Slope and LabConnect have unveiled their new bidirectional API integration. The solution builds on the existing collaboration between the organizations, offering a more comprehensive and seamless connection between Slope’s Biospecimen360 platform and LabConnect’s Laboratory Information Management System (LIMS).1
Marking the first integration of its kind in the clinical trial industry, it enables real-time, bidirectional data exchange. This includes all sample and subject metadata, as well as comprehensive kit and bulk supply inventory control from lab to site, at the site, and data-driven kit reordering back to LabConnect.
Key features of the new integration include:
- Elimination of common accessioning errors associated with paper-based requisitions.
- Removal of data discrepancies caused by duplicative data entry.
- Eradication of data entry delays typically seen with lab-specific portal e-requisitions.
- Complete control over kit inventory, sample metadata, and shipping processes.
“This enhanced integration marks a significant advancement in biospecimen management,” Rust Felix, CEO of Slope, said in a press release. “As part of our vendor-agnostic approach, Slope is committed to building an integrated lab ecosystem, with LabConnect as a key partner. This transformation sets a new standard for real-time data exchange in clinical trials, revolutionizing how the industry manages sample data and inventory.”
In the same press release, Wes Wheeler, CEO of LabConnect, added, “The integrity of assay results begins with the integrity of the sample. Our integration with Slope ensures that every step of the biospecimen lifecycle is monitored, controlled, and documented with unparalleled accuracy. This level of data integrity has never before been achieved in our industry.”
This new integration underscores Slope’s focus on standardizing data transfer, as well as streamlining traditional processes with new technology. From a Q&A with Applied Clinical Trials in April, Felix emphasized the industry’s challenges with ensuring data quality.
“One of the primary challenges the industry must confront is the issue of data quality and lack of standardization, especially in the context of biospecimen lifecycle management. Currently, the process is exceedingly manual, defined by paper-centric processes, complex sample management schemes, and an expanding volume of sample collections. The escalation in study complexity has precipitated a staggering increase in the number of procedures, endpoints, and data points collected, as evidenced by an analysis of nearly 10,000 clinical trial protocols,” he said.
Reference
1. Slope and LabConnect Unveil Groundbreaking Bidirectional API Integration for Clinical Trials. News release. Slope. November 25, 2024. Accessed November 27, 2024. https://www.prnewswire.com/news-releases/slope-and-labconnect-unveil-groundbreaking-bidirectional-api-integration-for-clinical-trials-302315037.html